{"contentid": 488603, "importid": NaN, "name": "Bayer lifted after first quarter financial results", "introduction": "Reporting first-quarter 2021 financial results, Bayer said sales of pharmaceuticals came in at 4.4 billion euros ($5.3 billion), a 4% fall from the prior-year period when currency effects are taken into account.", "content": "<p><span style=\"font-weight: 400;\">Reporting first-quarter 2021 financial results, Bayer (BAYN: DE) said sales of pharmaceuticals came in at 4.4 billion euros ($5.3 billion), a 4% fall from the prior-year period when currency effects are taken into account.</span></p>\n<p><span style=\"font-weight: 400;\">The unit reported earnings before interest, taxes, depreciation and amortization (EBIDTA) of 1.5 billion euros, down from 1.6 billion euros in the first quarter of 2020.</span></p>\n<p><span style=\"font-weight: 400;\">Bayer Group, which includes the German firm&rsquo;s consumer health and crop science businesses, took in 12.3 billion euros sales, a 4% drop, with net income of 2.1 billion euros.</span></p>\n<p><span style=\"font-weight: 400;\">After years of devastating litigation related to its fated $63 billion purchase of Monsanto, Bayer&rsquo;s crop science division appears to be </span><a href=\"https://www.thepharmaletter.com/article/bayer-agrees-10-billion-plus-deal-to-put-monsanto-roundup-litigation-behind-it\"><span style=\"font-weight: 400;\">turning a corner</span></a><span style=\"font-weight: 400;\">, and posted a 6.4% revenue increase in the first quarter.</span></p>\n<p><span style=\"font-weight: 400;\">Shares in the Leverkusen-based company opened up over 3% on Wednesday.</span></p>\n<h2>Pharmaceuticals</h2>\n<p>In the USA, Bayer&rsquo;s prescription medicines division benefited in particular from the launch of the cancer drug Nubeqa (darolutamide), an androgen receptor inhibitor.</p>\n<p>Another key growth market for the firm, China, was lifted by sales of oral anticoagulant Xarelto (rivaroxaban), while Glucobay (acarbose) and Avelox (moxifloxacin) struggled due to new tender procedures implemented in the country in 2020.</p>\n<p>A significant lift in sales of ophthalmology drug Eylea (aflibercept) - 15.8% - was driven by the Japanese, European, Chinese and Canadian markets, while oral contraceptives also grew strongly at 12.3%.</p>\n<p>On the down side, Bayer saw a distinct drop in sales of blood clotting medicines, and leading cancer drug Nexavar (sorafenib) was severely undercut by competition, with a 21% fall.</p>\n<p>Chief executive Werner Baumann said the firm was &ldquo;impacted by negative currency effects as expected,&rdquo; adding: &ldquo;Sales at Pharmaceuticals were steady, and in the Consumer Health Division we performed better than the competition.&rdquo;</p>\n<p>The company has reconfirmed its full year guidance for 2021 of adjusted EBITDA between 10.5 billion and 10.8 billion euros, down from the 11.46 billion 2020 figure.</p>\n<h2>Selected product performance</h2>\n<p>Xarelto (rivaroxaban) - Up 2.1% from 1.11 billion euros at 1.13 billion euros.</p>\n<p>Eylea (aflibercept) - Up 13.2% from 593 million euros at 671 million euros.</p>\n<p>Mirena/Kyleena/Jaydess (levonorgestrel) - Level at 319 million euros.</p>\n<p>Aspirin Cardio (acetylsalicylic acid) - Up 7.6% from 171 million euros at 184 million euros.</p>\n<p>Stivarga (regorafenib) - Level at 121 million euros.</p>", "date": "2021-05-12 10:48:00", "meta_title": NaN, "meta_keywords": "billion, euros, Bayer, sales, financial, results, pharmaceuticals, million, fall, quarter, reports, Leverkusen-based, first-quarter, Reporting, prior-year", "meta_description": "Reporting first-quarter financial results, Leverkusen-based Bayer said sales of pharmaceuticals came in at 4.4 billion euros ($5.3 billion), a 4% fall from the ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-12 10:22:46", "updated": "2021-05-12 10:49:28", "access": NaN, "url": "https://www.thepharmaletter.com/article/bayer-reports-financial-results-for-first-quarter", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bayer_big.jpg", "image2id": "bayer_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular, Oncology, Ophthalmics, Women's health", "topic_tag": "Financial, Management", "geography_tag": "Germany", "company_tag": "Bayer", "drug_tag": "Mirena, Nexavar, Nubeqa, Stivarga, Xarelto", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-12 10:48:00"}